Cover Image
市場調查報告書

Immune Response BioPharma, Inc. 的產品平台分析

Immune Response BioPharma Inc - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 319979
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Immune Response BioPharma, Inc. 的產品平台分析 Immune Response BioPharma Inc - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 42 Pages
簡介

Immune Response BioPharma, Inc.總公司在美國的製藥企業,開發自體免疫疾病和感染疾病的疫苗。該公司的產品使用於多發性硬化症、肺血性休克、HIV/AIDS、類風濕性關節炎、克隆氏症、乾癬等、痛風和糖尿病、心臟疾病等的治療。

本報告提供Immune Response BioPharma, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Immune Response BioPharma, Inc. 的基本資料

  • Immune Response BioPharma, Inc. 概要
  • 主要資訊
  • 企業資料

Immune Response BioPharma, Inc. :R&D概要

  • 主要的治療範圍

Immune Response BioPharma, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Immune Response BioPharma, Inc. :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Immune Response BioPharma, Inc. :藥物簡介

  • IR-103
  • IR-501
  • IR-703
  • IR-502
  • IR-902
  • RemuneX
  • IR-007
  • IR-1000
  • IR-1002
  • IR-2020
  • IR-222
  • IR-444
  • IR-555
  • IR-777
  • IR-888
  • IR-999

Immune Response BioPharma, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型

Immune Response BioPharma, Inc. :最近的開發平台資訊

Immune Response BioPharma, Inc. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08177CDB

Summary

Global Markets Direct's, 'Immune Response BioPharma Inc - Product Pipeline Review - 2016', provides an overview of the Immune Response BioPharma Inc's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immune Response BioPharma Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immune Response BioPharma Inc
  • The report provides overview of Immune Response BioPharma Inc including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immune Response BioPharma Inc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immune Response BioPharma Inc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immune Response BioPharma Inc's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immune Response BioPharma Inc
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immune Response BioPharma Inc's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Immune Response BioPharma Inc Snapshot
    • Immune Response BioPharma Inc Overview
    • Key Facts
  • Immune Response BioPharma Inc - Research and Development Overview
    • Key Therapeutic Areas
  • Immune Response BioPharma Inc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Immune Response BioPharma Inc - Pipeline Products Glance
    • Immune Response BioPharma Inc - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Immune Response BioPharma Inc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immune Response BioPharma Inc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Immune Response BioPharma Inc - Drug Profiles
    • IR-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-2020 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-222 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-444 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-502 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-555 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IR-999 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRE-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRR-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IRS-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Remune - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Immune Response BioPharma Inc - Pipeline Analysis
    • Immune Response BioPharma Inc - Pipeline Products by Target
    • Immune Response BioPharma Inc - Pipeline Products by Route of Administration
    • Immune Response BioPharma Inc - Pipeline Products by Molecule Type
  • Immune Response BioPharma Inc - Dormant Projects
  • Immune Response BioPharma Inc - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immune Response BioPharma Inc, Key Facts
  • Immune Response BioPharma Inc - Pipeline by Indication, 2016
  • Immune Response BioPharma Inc - Pipeline by Stage of Development, 2016
  • Immune Response BioPharma Inc - Monotherapy Products in Pipeline, 2016
  • Immune Response BioPharma Inc - Pre-Registration, 2016
  • Immune Response BioPharma Inc - Phase II, 2016
  • Immune Response BioPharma Inc - Phase I, 2016
  • Immune Response BioPharma Inc - Preclinical, 2016
  • Immune Response BioPharma Inc - Pipeline by Target, 2016
  • Immune Response BioPharma Inc - Pipeline by Route of Administration, 2016
  • Immune Response BioPharma Inc - Pipeline by Molecule Type, 2016
  • Immune Response BioPharma Inc - Dormant Developmental Projects,2016

List of Figures

  • Immune Response BioPharma Inc - Pipeline by Top 10 Indication, 2016
  • Immune Response BioPharma Inc - Pipeline by Stage of Development, 2016
  • Immune Response BioPharma Inc - Monotherapy Products in Pipeline, 2016
  • Immune Response BioPharma Inc - Pipeline by Route of Administration, 2016
  • Immune Response BioPharma Inc - Pipeline by Molecule Type, 2016
Back to Top